CN107823636A - A kind of medicine for treating tinnitus - Google Patents
A kind of medicine for treating tinnitus Download PDFInfo
- Publication number
- CN107823636A CN107823636A CN201711340568.8A CN201711340568A CN107823636A CN 107823636 A CN107823636 A CN 107823636A CN 201711340568 A CN201711340568 A CN 201711340568A CN 107823636 A CN107823636 A CN 107823636A
- Authority
- CN
- China
- Prior art keywords
- medicine
- injection
- treating tinnitus
- medication
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21001—Chymotrypsin (3.4.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of medicine for treating tinnitus, it is mainly prepared by hydrolysising protease, chymotrypsin, Cefoxitin, Edaravone by certain consumption proportion, medicine of the present invention has Stasis through, the promoting flow of qi and blood circulation, antibacterial, antiviral function, free radical can be removed, suppress vascular endothelial cell, the oxidative damage of nerve cell, treatment tinnitus effect is good, and cure rate is high.
Description
Technical field
The present invention relates to a kind of composition of medicine, especially a kind of medicine for treating tinnitus.
Background technology
Tinnitus is a kind of disease of ear, outer ear disease, otitis externa, impacted cerumen, external ear foreign matter, the acute and chronic of middle ear
Inflammation, the Meniere's syndrome of otospongiosis and inner ear, acoustic neurinoma, can cause tinnitus, be excessively used poisonous to ear
Property effect medicine, as gentamicin, streptomysin or kanamycins also may occur in which tinnitus.Tinnitus can make one to find it hard to concentrate,
The mood alterations such as worry is worried, depression, reach insufferable degree, and more somebody is reported to because seeking medical advice everywhere, bad to control,
There is no easy to handle ruling by law etc., often make patient have a rest owe, feel gloomy and in it is dizzy, brain is swollen, influences work and sleep, make one agitation not
Peace.
The content of the invention
It is an object of the invention to provide a kind of medicine for treating tinnitus, with solve the pain of tinnitus patient,
Another object of the present invention just there is provided the preparation application method of the medicine.
Embodiment
The solution of the present invention includes office's note medication and notes medication again.
First, dosage
1st, the dosage of office's note medication is as follows
Cacaine 2ml, prednisolone 0.1g, vitamin B1 0.1g；
2nd, the dosage for noting medication again is as follows
Hydrolysising protease 0.2g, chymotrypsin 0.1g, Cefoxitin 0.1g, Edaravone 0.1g, compound injection of red sage root
0.2ml。
2nd, prepare
1st, the preparation of office's injection thing
Cacaine, prednisolone, the vitamin B1 extracted respectively according to quantity, makes it be mixed into anesthetic；
2nd, the preparation of injection thing again
Hydrolysising protease, chymotrypsin, Cefoxitin, Edaravone, compound injection of red sage root are extracted according to quantity, make its mixing composition
To treat liquid, every time using 0.2ml.
3rd, the application method of medicine
1st, mastoid process cave is taken, anesthetic is injected in acupuncture point, strict aseptic technique, implements local anaesthesia；
2nd, it is placed in using negative-pressure cup on mastoid process acupuncture point, 0.1kp vacuum suction 3-4 minutes；
3rd, treatment liquid 0.2ml is extracted with puncture needle, injection treatment liquid in sclerotin is pierced into by mastoid process acupuncture point, then with adhesive bandage sealing label
Pinprick.
Drug hydrolysis protease of the present invention is antiseptic, has antiviral function；Chymotrypsin can promote blood block, purulence
The digestion of sexual secretion and slough is removed；Cefoxitin has stronger antibacterial functions；Edaravone is a kind of protective agent,
Free radical, anti-lipid peroxidation, so as to suppress the oxidative damage of vascular endothelial cell, nerve cell can be removed；Compound
The red sage root has Stasis through, the function of the promoting flow of qi and blood circulation, and the present invention combines said medicine so that each efficacy of drugs produces collaboration and made
With so as to effectively treat tinnitus.
Beneficial effects of the present invention are expanded on further with reference to test example.
[test example] accepts the people of tinnitus patient 36 for medical treatment, is injected and used to patient with above-mentioned application method, as a result shown, recovery from illness 34
People, 2 people recover, total effective rate 100%.
Claims (3)
1. a kind of medicine for treating tinnitus, including office note medication and note medication again, it is characterised in that：It is by following dosage respectively
Medicine made of：
（1）The dosage of office's note medication is as follows
Cacaine 2ml, prednisolone 0.1g, vitamin B1 0.1g；
（2）The dosage for noting medication again is as follows
Hydrolysising protease 0.2g, chymotrypsin 0.1g, Cefoxitin 0.1g, Edaravone 0.1g, compound injection of red sage root
0.2ml。
A kind of 2. preparation method for treating tinnitus medicine, it is characterised in that：It comprises the following steps：
（1）The preparation of office's injection thing
Cacaine, prednisolone, the vitamin B1 extracted respectively according to quantity, makes it be mixed into anesthetic；
（2）The preparation of injection thing again
Hydrolysising protease, chymotrypsin, Cefoxitin, Edaravone, compound injection of red sage root are extracted according to quantity, make its mixing composition
To treat liquid, every time using 0.2ml.
A kind of 3. application method for treating tinnitus medicine, it is characterised in that：Application method is as follows：
（1）Mastoid process cave is taken, anesthetic is injected in acupuncture point, strict aseptic technique, implements local anaesthesia；
（2）It is placed in using negative-pressure cup on mastoid process acupuncture point, 0.1kp vacuum suction 3-4 minutes；
（3）Treatment liquid 0.2ml is extracted with puncture needle, injection treatment liquid in sclerotin is pierced into by mastoid process acupuncture point, then sealed with adhesive bandage
Paste pinprick.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711340568.8A CN107823636A (en) | 2017-12-14 | 2017-12-14 | A kind of medicine for treating tinnitus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711340568.8A CN107823636A (en) | 2017-12-14 | 2017-12-14 | A kind of medicine for treating tinnitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107823636A true CN107823636A (en) | 2018-03-23 |
Family
ID=61644358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711340568.8A Withdrawn CN107823636A (en) | 2017-12-14 | 2017-12-14 | A kind of medicine for treating tinnitus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107823636A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102026623A (en) * | 2008-05-14 | 2011-04-20 | 奥德纳米有限公司 | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| CN102240357A (en) * | 2011-08-15 | 2011-11-16 | 江苏苏南药业实业有限公司 | Medicament for treating tinnitus and preparation method thereof |
| CN104435374A (en) * | 2014-12-29 | 2015-03-25 | 黑龙江中医药大学 | Acupoint injection for treating subjective tinnitus and preparation method of acupoint injection |
| CN106474153A (en) * | 2015-08-27 | 2017-03-08 | 沈敏辅 | Prevention or treatment phonosensitive nerve deafness or tinnitus include the pharmaceutical composition rich in hematoblastic blood plasma and its using method |
-
2017
- 2017-12-14 CN CN201711340568.8A patent/CN107823636A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102026623A (en) * | 2008-05-14 | 2011-04-20 | 奥德纳米有限公司 | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| CN102240357A (en) * | 2011-08-15 | 2011-11-16 | 江苏苏南药业实业有限公司 | Medicament for treating tinnitus and preparation method thereof |
| CN104435374A (en) * | 2014-12-29 | 2015-03-25 | 黑龙江中医药大学 | Acupoint injection for treating subjective tinnitus and preparation method of acupoint injection |
| CN106474153A (en) * | 2015-08-27 | 2017-03-08 | 沈敏辅 | Prevention or treatment phonosensitive nerve deafness or tinnitus include the pharmaceutical composition rich in hematoblastic blood plasma and its using method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shah et al. | Biopolymer-based biomaterials for accelerated diabetic wound healing: A critical review | |
| Ramadhinara et al. | Use of wireless microcurrent stimulation for the treatment of diabetes-related wounds: 2 case reports | |
| US20100310654A1 (en) | Homeopathic remedies for use before and after aesthetic injectable and surgical procedures to minimize swelling and bruising | |
| CN107823636A (en) | A kind of medicine for treating tinnitus | |
| CN1969992A (en) | Pharmaceutical composition for treating acne and application method thereof | |
| CN101890180A (en) | Wound dressing | |
| CN103479817A (en) | Wound healing gel | |
| CN105434467A (en) | Chilblain therapeutic agent and production method thereof | |
| Ji et al. | Sanguis draconis (Daemonorops draco): a case report of treating a chronic pressure ulcer with tunneling | |
| CN107469058A (en) | A kind of abdominal pain and distension patch | |
| CN203400332U (en) | Bromhidrosis-resistance silver fiber medicinal patch | |
| CN203042644U (en) | Aloe wound paste | |
| CN203763542U (en) | Collagen bandage | |
| CN104027391A (en) | Traditional Chinese medicine lotion for treating sweat stains | |
| RU2674445C1 (en) | Alcohol spray for external use | |
| CN107096094A (en) | A kind of delay pin with function promoting blood circulation and removing blood stasis fixes adhesive plaster | |
| RU2286761C1 (en) | Method for treating neurosensory impaired hearing | |
| Ollar | Physicians Take Heed of the Potential for the Appearance of Opportunistic Mycotic Infections in COVID-19 and Lyme Disease | |
| CN106551996A (en) | A kind of medicine for treating tinea pedis | |
| CN106581034A (en) | Drug used for treating rot of mouth and surrounding skin thereof caused by viruses | |
| CN1152714C (en) | A kind of film-replenishing ear drops medicinal preparation | |
| CN104257777A (en) | Traditional Chinese medicine composition for treating rhinitis, nasosinusitis and frontal sinusitis and preparation method of traditional Chinese medicine composition | |
| RU2020123217A (en) | Anti-SARS-CoV-2 virus agent Antiprovir | |
| CN111840387A (en) | A patch for preventing and treating influenza, and its preparation method | |
| CN110876765A (en) | Spray for treating rhinitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180323 |
|
| WW01 | Invention patent application withdrawn after publication |